CI has an uncertain future due to increasing rates of diagnosis and survival. Some policies have already removed conditions such as prostate cancer as the survival rates are now greatly improved.
Inevitably, if this type of cover does completely disappear or survives so that it only covers a few high-risk conditions, then this may prompt people to seek alternative forms of protection. IP should not, however, be viewed as a replacement for CI because each product provides for different needs and benefits. CI pays a lump sum on diagnosis of a range of serious illnesses. It could be described as life cover that pays out in advance of death and is valuable in providing people with financial help at a time of major upheaval. In contrast, IP steps in and continues to pay someone a 'sa...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
